Other attributes
Gregory T. Lucier (born 9 May 1964) is the Chairman and former CEO of NuVasive, Inc. He was previously CEO of DNA-sequencing company Life Technologies.
Lucier received his B.S. in Engineering at Pennsylvania State University, and earned his MBA from Harvard Business School.
Gregory T. Lucier has been the Chairman and CEO of NuVasive, Inc. since 2014, and serves as Chairman of the Board at Epic Sciences and Catalent Corporation (CTLT).
Earlier in his career, he was a corporate officer at General Electric. He was president of medical information technology at GE Healthcare, and was promoted to vice president of global services, the company's $2 billion healthcare services business.
In 2003, he left GE to join life sciences company Invitrogen. In 2008, Life Technologies was formed by the 2008 merger of Invitrogen and Applied Biosystems. Lucier became CEO and Chairman of the combined company. In 2011, he was #12 on Forbe's list of highest paid CEOs. He remained with the company until 2014, after selling the company to Thermo Fisher Scientific for $13.6 billion in 2013. In 2013, he had joined NuVasive's Board of Directors, and became the company's CEO in 2014.
Lucier has served on the Board of Directors at Invuity (now Stryker), CareFusion Corporation (now Becton Dickinson), Synthetic Genomics, Rady Children's Hospital, California Healthcare Institute and BIOCOM Inc.
